# Viavi Solutions Inc.: financial statements, quarterly VIAV · Nasdaq · CIK 912093 · [Technology](/sectors/technology.md) · fiscal year ends Jun 27 Pages: [Overview](/companies/viav.md) · [Financials](/companies/viav/financials.md) · [Filings](/companies/viav/filings.md) · [Insiders](/companies/viav/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/viav/financials.md?period=annual). ## Income statement | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | Q4 FY2024 (2024-06-29) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | Q4 FY2025 (2025-06-28) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | Q4 FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [248](/filings/0000912093-24-000093.md) | [255](/filings/0000912093-25-000012.md) | [246](/filings/0000912093-25-000028.md) | [252 d](/filings/0001628280-26-056765.md) | [238](/filings/0000912093-25-000153.md) | [271](/filings/0001628280-26-004138.md) | [285](/filings/0001628280-26-028926.md) | [291 d](/filings/0001628280-26-056765.md) | [299](/filings/0000912093-25-000153.md) | [369](/filings/0001628280-26-004138.md) | [407](/filings/0001628280-26-028926.md) | [443 d](/filings/0001628280-26-056765.md) | | Cost of revenue | $m | [104](/filings/0000912093-24-000093.md) | [107](/filings/0000912093-25-000012.md) | [108](/filings/0000912093-25-000028.md) | [106 d](/filings/0001628280-26-056765.md) | [102](/filings/0000912093-25-000153.md) | [110](/filings/0001628280-26-004138.md) | [124](/filings/0001628280-26-028926.md) | [127 d](/filings/0001628280-26-056765.md) | [130](/filings/0000912093-25-000153.md) | [159](/filings/0001628280-26-004138.md) | [173](/filings/0001628280-26-028926.md) | [181 d](/filings/0001628280-26-056765.md) | | Gross profit | $m | [144](/filings/0000912093-24-000093.md) | [148](/filings/0000912093-25-000012.md) | [138](/filings/0000912093-25-000028.md) | [146 d](/filings/0001628280-26-056765.md) | [136](/filings/0000912093-25-000153.md) | [161](/filings/0001628280-26-004138.md) | [161](/filings/0001628280-26-028926.md) | [164 d](/filings/0001628280-26-056765.md) | [169](/filings/0000912093-25-000153.md) | [211](/filings/0001628280-26-004138.md) | [234](/filings/0001628280-26-028926.md) | [262 d](/filings/0001628280-26-056765.md) | | Research and development | $m | [49.9](/filings/0000912093-24-000093.md) | [49.5](/filings/0000912093-25-000012.md) | [50.0](/filings/0000912093-25-000028.md) | [52.5 d](/filings/0001628280-26-056765.md) | [49.4](/filings/0000912093-25-000153.md) | [52.1](/filings/0001628280-26-004138.md) | [50.0](/filings/0001628280-26-028926.md) | [57.2 d](/filings/0001628280-26-056765.md) | [56.0](/filings/0000912093-25-000153.md) | [65.9](/filings/0001628280-26-004138.md) | [71.0](/filings/0001628280-26-028926.md) | [69.8 d](/filings/0001628280-26-056765.md) | | Selling, general and administrative | $m | [77.2](/filings/0000912093-24-000093.md) | [74.8](/filings/0000912093-25-000012.md) | [98.2](/filings/0000912093-25-000028.md) | [83.1 d](/filings/0001628280-26-056765.md) | [74.1](/filings/0000912093-25-000153.md) | [84.3](/filings/0001628280-26-004138.md) | [101](/filings/0001628280-26-028926.md) | [89.7 d](/filings/0001628280-26-056765.md) | [104](/filings/0000912093-25-000153.md) | [127](/filings/0001628280-26-004138.md) | [114](/filings/0001628280-26-028926.md) | [124 d](/filings/0001628280-26-056765.md) | | Operating income | $m | [16.0](/filings/0000912093-24-000093.md) | [22.4](/filings/0000912093-25-000012.md) | [(11.9)](/filings/0000912093-25-000028.md) | [(5.7) d](/filings/0001628280-26-056765.md) | [11.5](/filings/0000912093-25-000153.md) | [22.2](/filings/0001628280-26-004138.md) | [8.5](/filings/0001628280-26-028926.md) | [15.3 d](/filings/0001628280-26-056765.md) | [7.6](/filings/0000912093-25-000153.md) | [11.4](/filings/0001628280-26-004138.md) | [24.8](/filings/0001628280-26-028926.md) | [61.3 d](/filings/0001628280-26-056765.md) | | Interest expense | $m | [7.8](/filings/0000912093-23-000059.md) | [7.9](/filings/0000912093-24-000009.md) | [7.7](/filings/0000912093-24-000033.md) | [7.5 d](/filings/0001628280-26-056765.md) | [7.5](/filings/0000912093-25-000153.md) | [7.5](/filings/0001628280-26-004138.md) | [7.5](/filings/0001628280-26-028926.md) | [7.5 d](/filings/0001628280-26-056765.md) | [7.4](/filings/0000912093-25-000153.md) | [15.3](/filings/0001628280-26-004138.md) | [14.3](/filings/0001628280-26-028926.md) | [10.4 d](/filings/0001628280-26-056765.md) | | Income tax | $m | [8.6](/filings/0000912093-24-000093.md) | [7.6](/filings/0000912093-25-000012.md) | [9.0](/filings/0000912093-25-000028.md) | [12.2 d](/filings/0001628280-26-056765.md) | [9.0](/filings/0000912093-25-000153.md) | [9.5](/filings/0001628280-26-004138.md) | [(16.3)](/filings/0001628280-26-028926.md) | [2.2 d](/filings/0001628280-26-056765.md) | [19.0](/filings/0000912093-25-000153.md) | [9.7](/filings/0001628280-26-004138.md) | [7.4](/filings/0001628280-26-028926.md) | [11.4 d](/filings/0001628280-26-056765.md) | | Net income | $m | [9.8](/filings/0000912093-24-000093.md) | [10.7](/filings/0000912093-25-000012.md) | [(24.6)](/filings/0000912093-25-000028.md) | [(21.7) d](/filings/0001628280-26-056765.md) | [(1.8)](/filings/0000912093-25-000153.md) | [9.1](/filings/0001628280-26-004138.md) | [19.5](/filings/0001628280-26-028926.md) | [8.0 d](/filings/0001628280-26-056765.md) | [(21.4)](/filings/0000912093-25-000153.md) | [(48.1)](/filings/0001628280-26-004138.md) | [6.4](/filings/0001628280-26-028926.md) | [32.7 d](/filings/0001628280-26-056765.md) | | Diluted EPS | $ per share | [0.04](/filings/0000912093-24-000093.md) | [0.05](/filings/0000912093-25-000012.md) | [(0.11)](/filings/0000912093-25-000028.md) | not reported | [(0.01)](/filings/0000912093-25-000153.md) | [0.04](/filings/0001628280-26-004138.md) | [0.09](/filings/0001628280-26-028926.md) | not reported | [(0.10)](/filings/0000912093-25-000153.md) | [(0.21)](/filings/0001628280-26-004138.md) | [0.03](/filings/0001628280-26-028926.md) | not reported | | Basic EPS | $ per share | [0.04](/filings/0000912093-24-000093.md) | [0.05](/filings/0000912093-25-000012.md) | [(0.11)](/filings/0000912093-25-000028.md) | not reported | [(0.01)](/filings/0000912093-25-000153.md) | [0.04](/filings/0001628280-26-004138.md) | [0.09](/filings/0001628280-26-028926.md) | not reported | [(0.10)](/filings/0000912093-25-000153.md) | [(0.21)](/filings/0001628280-26-004138.md) | [0.03](/filings/0001628280-26-028926.md) | not reported | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | FY2024 (2024-06-29) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | FY2025 (2025-06-28) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [521](/filings/0000912093-23-000059.md) | [544](/filings/0000912093-24-000009.md) | [454](/filings/0000912093-24-000033.md) | [471](/filings/0000912093-25-000096.md) | [468](/filings/0000912093-24-000093.md) | [488](/filings/0000912093-25-000012.md) | [374](/filings/0000912093-25-000028.md) | [424](/filings/0001628280-26-056765.md) | [544](/filings/0000912093-25-000153.md) | [766](/filings/0001628280-26-004138.md) | [499](/filings/0001628280-26-028926.md) | [648](/filings/0001628280-26-056765.md) | | Current assets | $m | [916](/filings/0000912093-23-000059.md) | [965](/filings/0000912093-24-000009.md) | [868](/filings/0000912093-24-000033.md) | [877](/filings/0000912093-25-000096.md) | [864](/filings/0000912093-24-000093.md) | [880](/filings/0000912093-25-000012.md) | [835](/filings/0000912093-25-000028.md) | [885](/filings/0001628280-26-056765.md) | [990](/filings/0000912093-25-000153.md) | [1,279](/filings/0001628280-26-004138.md) | [1,054](/filings/0001628280-26-028926.md) | [1,257](/filings/0001628280-26-056765.md) | | Total assets | $m | [1,802](/filings/0000912093-23-000059.md) | [1,856](/filings/0000912093-24-000009.md) | [1,744](/filings/0000912093-24-000033.md) | [1,736](/filings/0001628280-26-056765.md) | [1,738](/filings/0000912093-25-000153.md) | [1,725](/filings/0000912093-25-000012.md) | [1,933](/filings/0000912093-25-000028.md) | [1,994](/filings/0001628280-26-056765.md) | [2,082](/filings/0000912093-25-000153.md) | [2,778](/filings/0001628280-26-004138.md) | [2,528](/filings/0001628280-26-028926.md) | [2,706](/filings/0001628280-26-056765.md) | | Current liabilities | $m | [311](/filings/0000912093-23-000059.md) | [312](/filings/0000912093-24-000009.md) | [228](/filings/0000912093-24-000033.md) | [247](/filings/0000912093-25-000096.md) | [233](/filings/0000912093-24-000093.md) | [248](/filings/0000912093-25-000012.md) | [545](/filings/0000912093-25-000028.md) | [590](/filings/0001628280-26-056765.md) | [498](/filings/0000912093-25-000153.md) | [490](/filings/0001628280-26-004138.md) | [653](/filings/0001628280-26-028926.md) | [681](/filings/0001628280-26-056765.md) | | Total liabilities | $m | not reported | not reported | not reported | [1,055](/filings/0000912093-25-000096.md) | [1,036](/filings/0000912093-24-000093.md) | [1,042](/filings/0000912093-25-000012.md) | [1,204](/filings/0000912093-25-000028.md) | [1,214](/filings/0001628280-26-056765.md) | [1,358](/filings/0000912093-25-000153.md) | [1,944](/filings/0001628280-26-004138.md) | [1,681](/filings/0001628280-26-028926.md) | [1,257](/filings/0001628280-26-056765.md) | | Long-term debt | $m | [631](/filings/0000912093-23-000059.md) | [633](/filings/0000912093-24-000009.md) | [634](/filings/0000912093-24-000033.md) | [636](/filings/0000912093-25-000028.md) | [638](/filings/0000912093-24-000093.md) | [639](/filings/0000912093-25-000012.md) | [396](/filings/0000912093-25-000028.md) | [396](/filings/0001628280-26-028926.md) | [641](/filings/0000912093-25-000153.md) | [1,222](/filings/0001628280-26-004138.md) | [836](/filings/0001628280-26-028926.md) | not reported | | Current portion of debt | $m | [96.2](/filings/0000912093-23-000059.md) | [96.3](/filings/0000912093-24-000009.md) | [0.0](/filings/0000912093-24-000033.md) | [0.0](/filings/0000912093-25-000028.md) | not reported | not reported | [245](/filings/0000912093-25-000028.md) | [246](/filings/0001628280-26-056765.md) | [151](/filings/0000912093-25-000153.md) | [53.4](/filings/0001628280-26-004138.md) | [245](/filings/0001628280-26-028926.md) | [245](/filings/0001628280-26-056765.md) | | Short-term borrowings | $m | not reported | not reported | not reported | [0.0](/filings/0000912093-25-000096.md) | not reported | not reported | not reported | [246](/filings/0001628280-26-056765.md) | not reported | not reported | not reported | [245](/filings/0001628280-26-056765.md) | | Shareholders' equity | $m | [675](/filings/0000912093-25-000012.md) | [728](/filings/0000912093-25-000028.md) | [705](/filings/0000912093-25-000028.md) | [682](/filings/0001628280-26-056765.md) | [702](/filings/0001628280-26-004138.md) | [683](/filings/0001628280-26-028926.md) | [729](/filings/0001628280-26-028926.md) | [780](/filings/0001628280-26-056765.md) | [724](/filings/0001628280-26-004138.md) | [834](/filings/0001628280-26-028926.md) | [847](/filings/0001628280-26-028926.md) | [1,449](/filings/0001628280-26-056765.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt - Current portion of debt: us-gaap:DebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | Q4 FY2024 (2024-06-29) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | Q4 FY2025 (2025-06-28) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | Q4 FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [50.3](/filings/0000912093-24-000093.md) | [20.4 d](/filings/0000912093-25-000012.md) | [19.5 d](/filings/0000912093-25-000028.md) | [26.2 d](/filings/0001628280-26-056765.md) | [13.5](/filings/0000912093-25-000153.md) | [44.7 d](/filings/0001628280-26-004138.md) | [7.8 d](/filings/0001628280-26-028926.md) | [23.8 d](/filings/0001628280-26-056765.md) | [31.0](/filings/0000912093-25-000153.md) | [42.5 d](/filings/0001628280-26-004138.md) | [(26.3) d](/filings/0001628280-26-028926.md) | [66.7 d](/filings/0001628280-26-056765.md) | | Capital expenditure | $m | [6.7](/filings/0000912093-24-000093.md) | [5.8 d](/filings/0000912093-25-000012.md) | [3.2 d](/filings/0000912093-25-000028.md) | [3.8 d](/filings/0001628280-26-056765.md) | [7.3](/filings/0000912093-25-000153.md) | [8.2 d](/filings/0001628280-26-004138.md) | [6.8 d](/filings/0001628280-26-028926.md) | [5.5 d](/filings/0001628280-26-056765.md) | [8.5](/filings/0000912093-25-000153.md) | [5.6 d](/filings/0001628280-26-004138.md) | [5.9 d](/filings/0001628280-26-028926.md) | [11.1 d](/filings/0001628280-26-056765.md) | | Share repurchases | $m | [10.0](/filings/0000912093-24-000093.md) | [0.0 d](/filings/0000912093-25-000012.md) | [0.0 d](/filings/0000912093-25-000028.md) | [10.0 d](/filings/0001628280-26-056765.md) | [16.4](/filings/0000912093-25-000153.md) | [0.0 d](/filings/0001628280-26-004138.md) | [0.0 d](/filings/0001628280-26-028926.md) | [0.0 d](/filings/0001628280-26-056765.md) | [30.0](/filings/0000912093-25-000153.md) | [0.0 d](/filings/0001628280-26-004138.md) | [0.0 d](/filings/0001628280-26-028926.md) | [0.0 d](/filings/0001628280-26-056765.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-04-01) | Q4 FY2023 (2023-07-01) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [227](/filings/0000912093-24-000009.md) | [224](/filings/0000912093-24-000033.md) | [222](/filings/0000912093-23-000037.md) | [224](/filings/0000912093-24-000093.md) | [224](/filings/0000912093-25-000012.md) | [223](/filings/0000912093-25-000028.md) | [222](/filings/0000912093-25-000153.md) | [225](/filings/0001628280-26-004138.md) | [227](/filings/0001628280-26-028926.md) | [223](/filings/0000912093-25-000153.md) | [224](/filings/0001628280-26-004138.md) | [250](/filings/0001628280-26-028926.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 246,749,828 at 2026-07-28, from the cover of the [10-K filed 2026-08-13](/filings/0001628280-26-056765.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.